Researchers Submit Patent Application, "Formulations Of Anti-Pd1 Antibodies", for Approval (USPTO 20240287185).

A patent application has been submitted for the approval of formulations of anti-PD1 antibodies. PD-1 is a cell surface protein that regulates immune responses, and inhibiting its interaction with PD-L1 can enhance T cell responses and mediate antitumor activity. Several antibodies targeting PD-1 have been developed, including pembrolizumab and nivolumab. The patent application describes liquid pharmaceutical compositions containing an anti-PD1 antibody, amino acids, a non-ionic surfactant, and citrate buffer, with a pH between 5.0 and 5.8. These compositions may be used for the treatment of various cancers. [Extracted from the article]